Drugs / Tefinostat
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00820508 | Dec 2008 → Jul 2011 | lymphoma | Chroma Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02759601 | Jan 2013 → Dec 2018 | hepatocellular carcinoma | Queen Mary University of London | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tefinostat | “Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase inhibitor (HDACi).” PMID 23647373 ↗ May 2013 |
| Known as | CHR-2845 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00820508 ↗ |
| Action | Inhibit | “Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase inhibitor (HDACi).” PMID 23647373 ↗ May 2013 |
| Modality | Small molecule | — CHEMBL4297582 ↗ |
| Route | Oral | “oral, once daily tefinostat” PMID 23647373 ↗ May 2013 |